Skip to main content
Clinical Trials/IRCT20210626051716N1
IRCT20210626051716N1
Completed
N/A

Comparison of the Effect of Rhythmic Respiration and Lidocaine Spray on the Severity of Arteriovenous Fistula Venipuncture Pain in Patients undergoing hemodialysis

Gonabad University of Medical Sciences0 sites54 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Severity of Arteriovenous Fistula Venipuncture Pain in Patients undergoing Hemodialysis.
Sponsor
Gonabad University of Medical Sciences
Enrollment
54
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Gonabad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Be between 18 and 60 years old
  • Willing to cooperate and participate in research
  • At least 3 months have passed since the fistula was implanted
  • Lack of pacemaker
  • Having an active record so that three sessions per week and each session for 4 hours to be treated with Hemodialysis
  • Absence of skin problems, lack of anesthesia, neuropathic disorders and peripheral vascular diseases at the fistula site
  • If you have diabetes, have controlled diabetes (FBS samples in the range of 70 to 150 and BS in the range of 120 to 250\)
  • Do not have verbal, visual or auditory impairment
  • Lack of known allergy to Lidocaine
  • Do not have drug addiction and dependence on painkillers

Exclusion Criteria

  • Do not want to continue collaborating in research
  • Lack of patient awareness at any stage of the research
  • Failure of the needle to enter the arteries of the fistula area in the first attempt and the need to repeat the Cannulation
  • Incidence of Lidocaine sensitivity at any stage of the study
  • Onset of other chronic pain that affects the assessment of pain due to needle insertion into the fistula
  • Failure to refer to the research stages (refer to other medical centers to continue treatment, travel, kidney transplant, death)

Outcomes

Primary Outcomes

Not specified

Similar Trials